# US 7,744,876 B2 · Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,876 B2
- Document ID: US7744876B2
- Status: Granted
- Kind: B2
- Application number: 10/510,411
- Filed: 2003-04-08
- Published: 2006-09-21
- Granted: 2010-06-29
- Earliest claimed: 2002-04-09
- Assignees: The Curators of the University of Missouri
- Inventors: Habib Zaghouani; Randal Keith Gregg
- Web page: https://patentgrep.com/patent/US7744876B2

## CPC

- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes. More specifically, the present invention relates to the administration of a fusion protein comprising at least one immunoglobulin having one or more diabetogenic epitopes inserted within the variable region, for suspending, preventing or delaying the onset of type 1 diabetes.

## Claims

### Claim 1

A soluble immunoglobulin-polypeptide chimera comprising an immunoglobulin having a CDR3 region, wherein a diabetogenic epitope comprising a polypeptide having amino acid sequence of SEQ ID No: 4 is inserted within the CDR3 region.

### Claim 2 (depends on 1)

The chimera of claim 1 wherein the immunoglobulin comprises IgG.

### Claim 3 (depends on 2)

The chimera of claim 2 wherein said IgG is human IgG or humanized IgG.

### Claim 4 (depends on 1)

The chimera of claim 1, wherein the at least one diabetogenic epitope replaces a D segment within said CDR3 region.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a chimera according to claim 1 and a pharmaceutically acceptable carrier.